BioFilm Control



BioFilm Control is a Biotechnology R&D company, formed in 2004, which has developed one-of-a-kind proprietary technology using magnetisable microbeads, protected by 7 patents and 9 trademarks. This technology detects the biofilm behaviour of microorganisms and was automated in 2009. This is the only “biofilm” technology in Medical Analysis Laboratories (Public or Private institutions).
BioFilm Control markets BioFilm Ring Test® and Antibiofilmogram® kits in 96-well plate format for research use only. The Antibiofilmogram® kits study the susceptibility of bacteria to antibiotics, both in planktonic and biofilm populations. Three panels of 11 antibiotics are available, defined for Staphylococcus aureus (in Bone & joint infections and Diabetic Foot), Escherichia coli (in Urinary Tract Infections), Pseudomonas aeruginosa (in Cystic fibrosis and Pulmonary infections). Clinical protocols are under way and the first MD-IVD versions with CE marking are scheduled for 2017.
The company also operates its biofilm expertise under R&D (pharmaceutical industry – human health and veterinary applications-, cosmetics industry, food, hygiene, etc).
BioFilm Control currently employs 11 people working in premises of 400m², 90m² of which dedicated to a P2 laboratory. The team is made up of 2 directors-researchers, one Project Manager, one administrative assistant and 7 engineers/technicians. BioFilm Control is also backed by a Scientific Committee made up of: Prof. Kaplan, Ph.D. American University, Washington (inventor of the first antibiofilm agent, Dispersin B), Pr McArthur, M.D., Ph.D., University of Missouri, Kansas City (expert on Mycobacterium tuberculosis, on HIV, on Diagnostic tests), Prof. Tulkens, Univ. Catholique Louvain (one of the founders of EUCAST), Dr Jehl, CHU Strasbourg (Chairman of the French Antibiogram Committee), Dr Laurent, AP-HP Lyon (reference for Bone & Joint Infections), Prof. Lavigne and Prof. Sotto, CHU Nîmes (Diabetic Foot reference)…



Sub-project 11: Development of innovative tools for rapid phenotypic characterisation of intraspecific diversity




Thierry BERNARDI is the founder of BioFilm Control as well as the inventor of the BioFilm Ring Test®


Pharm.D in 1991 from the University of Montpellier (France)

Professional and teaching experience

Prior to founding BioFilm Control, he held several technical, general management and business development positions intechnical, general management and business development positions in start-ups (Nucleica, GeneSystems) and multinational companies (SANOFI, Perkin Elmer, Applied Biosystems).

Research Interests

R&D in Biotechnologies, Diagnostics and Pharmacy.

Main publications:


  • “Method and device for detecting the formation and development of biofilms in a culture medium”.BERNARDI, Thierry, BARA, Nicolas.Priority FR 2004/0001791; 23.02.2004. WO 2005/090944; 29.09.2005.

  • “Method and device for isolating micro-organisms”. BARA, Nicolas, BERNARDI, Thierry. Priority FR 2005/0002553, 15.03.2005. WO 2006/097631, 21.09.2006.

  • “Method for reading images, in particular for studying the development of biofilm in
    a culture medium”. BERNARDI, Thierry, BARA, Nicolas. Priority FR 2006/0002145 ; 10.03.2006. WO 2007/104881; 08.03.2007

  • “Method for determining the sensitivity of microorganism to antibiotic, which prevents biofilm development, comprises introducing magnetic/magnetizable particle to liquid culture medium, inoculating the medium with microorganism and adding antibiotic”. BERNARDI, Thierry, FR20070055344, 30.05.2007.

  • “Method for detecting molecular interactions”. BERNARDI, Thierry, MAYER, Pascal, GROELLY, Jerome. Priority FR 1002810, 02.07.2010. WO 2012/001312 ; 05.01.2012.

  • “Method for measuring the resistance of films”. BERNARDI, Thierry, MAYER, Pascal, GROELLY, Jerome. Priority FR 1060960, 21.12.2010.WO 2012/085468 ; 28.06.2012.

  • “Rapid antibiogram”. BERNARDI, Thierry, GROELLY J. Priority FR 2014/050748; 28.03.2013. WO 2014/155020 ; 02.10.2014


Christian PROVOT


Christian PROVOT is the CSO of the company. He joined BioFilm Control in June 2013


Ph.D. in cellular and molecular biology

Professional and teaching experience

22 years of experience in R&D applied to manual or High Throughput Screening diagnostics in healthcare, cosmetics, pharmacy and the food sectors using molecular and immunological biology methods (ELISA with optical, fluorescence or luminometric detection, q(RT)-PCR ..).

Research Interests

R&D in diagnostic methods


  • Method for the qualitative and quantitative detection of DNA damage. US 6261767.

  • Method for detecting qualitative and quantitative alterations in DNA and ligands of said alteration ligands. US 6309838.

  • Method for amplifying all of the DNA fragments in a sample, including small and damaged fragments, by pretreating the fragments with P1 nuclease. US 6605435.


See the others partners beneficiaries

See the associated partners


eulogoThis project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Curie grant agreement n° 641984

Suivez-nous sur :